Noninvasive Assessment of Excessive Erythrocytosis as a Screening Method for Chronic Mountain Sickness at High Altitude
| Autor: | Robert A. Wise, Kaetan J. Vyas, Fabiola León-Velarde, J. Jaime Miranda, David Danz, Robert H. Gilman, William Checkley |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male Scientific Articles medicine.medical_specialty purl.org/pe-repo/ocde/ford#3.03.05 [https] Physiology Point-of-Care Systems Hematologic Tests/instrumentation/statistics & numerical data Polycythemia Altitude Sickness Hemoglobins/analysis Sensitivity and Specificity Altitude Sickness/blood/diagnosis Hemoglobins noninvasive methods Peru Screening method Humans Polycythemia/blood Medicine Point-of-Care Systems/statistics & numerical data excessive erythrocytosis Oxyhemoglobin saturation Altitude sickness chronic mountain sickness Aged Hematologic Tests Hematologic tests purl.org/pe-repo/ocde/ford#3.01.08 [https] business.industry Altitude screening Public Health Environmental and Occupational Health Reproducibility of Results General Medicine Venous blood Middle Aged Effects of high altitude on humans medicine.disease purl.org/pe-repo/ocde/ford#3.03.11 [https] Total hemoglobin Chronic mountain sickness Chronic Disease Emergency medicine Physical therapy Female business |
| Zdroj: | High Altitude Medicine & Biology. 16:162-168 |
| ISSN: | 1557-8682 1527-0297 |
| Popis: | Vyas, Kaetan J., David Danz, Robert H. Gilman, Robert A. Wise, Fabiola León-Velarde, J. Jaime Miranda, and William Checkley. Noninvasive assessment of excessive erythrocytosis as a screening method for chronic mountain sickness at high altitude. High Alt Med Biol 16:162–168, 2015.—Globally, over 140 million people are at risk of developing chronic mountain sickness, a common maladaptation to life at high altitude (>2500 meters above sea level). The diagnosis is contingent upon the identification of excessive erythrocytosis (EE). Current best practices to identify EE require a venous blood draw, which is cumbersome for large-scale surveillance. We evaluated two point-of-care biomarkers to screen for EE: noninvasive spot-check tests of total hemoglobin and oxyhemoglobin saturation (Pronto-7, Masimo Corporation). We conducted paired evaluations of total serum hemoglobin from a venous blood draw and noninvasive, spot-check testing of total hemoglobin and oxyhemoglobin saturation with the Pronto-7 in 382 adults aged ≥35 years living in Puno, Peru (3825 meters above sea level). We used the Bland-Altman method to measure agreement between the noninvasive hemoglobin assessment and the gold standard lab hemoglobin analyzer. Mean age was 58.8 years and 47% were male. The Pronto-7 test was unsuccessful in 21 (5%) participants. Limits of agreement between total hemoglobin measured via venous blood draw and the noninvasive, spot-check test ranged from −2.8 g/dL (95% CI −3.0 to −2.5) to 2.5 g/dL (95% CI 2.2 to 2.7), with a bias of −0.2 g/dL (95% CI −0.3 to −0.02) for the difference between total hemoglobin and noninvasive hemoglobin concentrations. Overall, the noninvasive spot-check test of total hemoglobin had a better area under the receiver operating characteristic curve compared to oxyhemoglobin saturation for the identification of EE as measured by a gold standard laboratory hemoglobin analyzer (0.96 vs. 0.82; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|